BRPI1010820A2 - desfesoterodina na forma de um sal de acido tartarico - Google Patents
desfesoterodina na forma de um sal de acido tartaricoInfo
- Publication number
- BRPI1010820A2 BRPI1010820A2 BRPI1010820A BRPI1010820A BRPI1010820A2 BR PI1010820 A2 BRPI1010820 A2 BR PI1010820A2 BR PI1010820 A BRPI1010820 A BR PI1010820A BR PI1010820 A BRPI1010820 A BR PI1010820A BR PI1010820 A2 BRPI1010820 A2 BR PI1010820A2
- Authority
- BR
- Brazil
- Prior art keywords
- desesoterodine
- acid salt
- tartaric acid
- tartaric
- salt
- Prior art date
Links
- 150000003892 tartrate salts Chemical class 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C211/00—Compounds containing amino groups bound to a carbon skeleton
- C07C211/62—Quaternary ammonium compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
- C07C215/46—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
- C07C215/48—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by hydroxy groups
- C07C215/54—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by hydroxy groups linked by carbon chains having at least three carbon atoms between the amino groups and the six-membered aromatic ring or the condensed ring system containing that ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
- A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
- A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
- A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/235—Saturated compounds containing more than one carboxyl group
- C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
- C07C59/255—Tartaric acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Emergency Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Urology & Nephrology (AREA)
- Communicable Diseases (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP09006357 | 2009-05-11 | ||
| EP09006848 | 2009-05-20 | ||
| EP09013104 | 2009-10-16 | ||
| PCT/EP2010/002858 WO2010130392A1 (de) | 2009-05-11 | 2010-05-10 | Desfesoterodin in form eines weinsäuresalzes |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI1010820A2 true BRPI1010820A2 (pt) | 2019-09-24 |
Family
ID=42668621
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI1010820A BRPI1010820A2 (pt) | 2009-05-11 | 2010-05-10 | desfesoterodina na forma de um sal de acido tartarico |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US9085507B2 (pt) |
| EP (1) | EP2416761B1 (pt) |
| KR (1) | KR20120014583A (pt) |
| BR (1) | BRPI1010820A2 (pt) |
| CA (1) | CA2761602C (pt) |
| ES (1) | ES2533956T3 (pt) |
| IL (1) | IL216224A0 (pt) |
| MX (1) | MX2011011937A (pt) |
| PL (1) | PL2416761T3 (pt) |
| WO (1) | WO2010130392A1 (pt) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9440910B2 (en) * | 2012-05-18 | 2016-09-13 | Alembic Pharmaceuticals Limited | Reference markers for fesoterodine fumarate |
| PL2760822T3 (pl) | 2012-06-14 | 2016-09-30 | Sole desfezoterodyny | |
| PL3294270T3 (pl) * | 2016-03-24 | 2019-02-28 | Sandoz Ag | Farmaceutyczna kompozycja zawierająca rifaksyminę alfa i delta |
| PL3792260T3 (pl) | 2018-05-08 | 2024-12-02 | Nippon Shinyaku Co., Ltd. | Związki azabenzimidazolowe i środki farmaceutyczne |
| WO2021095801A1 (ja) | 2019-11-13 | 2021-05-20 | 日本新薬株式会社 | アザベンゾイミダゾール化合物及び医薬 |
| IL324862A (en) * | 2023-05-25 | 2026-01-01 | Maplight Therapeutics Inc | Compounds for the treatment of neurological disorders |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE8800207D0 (sv) * | 1988-01-22 | 1988-01-22 | Kabivitrum Ab | Nya aminer, deras anvendning och framstellning |
| US5382600A (en) * | 1988-01-22 | 1995-01-17 | Pharmacia Aktiebolag | 3,3-diphenylpropylamines and pharmaceutical compositions thereof |
| SE9203318D0 (sv) * | 1992-11-06 | 1992-11-06 | Kabi Pharmacia Ab | Novel 3,3-diphenylpropylamines, their use and preparation |
| EP0957073A1 (en) | 1998-05-12 | 1999-11-17 | Schwarz Pharma Ag | Novel derivatives of 3,3-diphenylpropylamines |
| DE19932651A1 (de) | 1999-07-13 | 2001-01-18 | Hexal Ag | Transdermales therapeutisches System zur Anwendung von Tolterodin |
| DE29923134U1 (de) | 1999-11-16 | 2000-06-29 | Schwarz Pharma Ag, 40789 Monheim | Stabile Salze neuartiger Derviate von 3,3-Diphenylpropylaminen |
| US7005449B2 (en) * | 2002-04-23 | 2006-02-28 | Pharmacia & Upjohn Company | Tolterodine salts |
| WO2005012227A2 (en) | 2003-08-05 | 2005-02-10 | Ranbaxy Laboratories Limited | Process for preparation of 2-(3-diisopropylamino-1-phenylpropyl)-4-hydroxymethyl-phenol, a metabolite of tolterodine |
| KR101087326B1 (ko) | 2006-05-24 | 2011-11-25 | 화이자 리미티드 | 벤조피란-2-올 유도체의 생성 방법 |
| AP2416A (en) | 2006-06-09 | 2012-06-01 | Sanol Arznei Schwarz Gmbh | Stabilized pharmaceutical compositions comprising fesoterodine. |
| JP2011502140A (ja) * | 2007-10-29 | 2011-01-20 | ルピン・リミテッド | トルテロジンの制御放出型医薬組成物 |
-
2010
- 2010-05-10 BR BRPI1010820A patent/BRPI1010820A2/pt not_active IP Right Cessation
- 2010-05-10 MX MX2011011937A patent/MX2011011937A/es not_active Application Discontinuation
- 2010-05-10 PL PL10720884T patent/PL2416761T3/pl unknown
- 2010-05-10 WO PCT/EP2010/002858 patent/WO2010130392A1/de not_active Ceased
- 2010-05-10 US US13/319,746 patent/US9085507B2/en not_active Expired - Fee Related
- 2010-05-10 CA CA2761602A patent/CA2761602C/en not_active Expired - Fee Related
- 2010-05-10 EP EP10720884.5A patent/EP2416761B1/de not_active Not-in-force
- 2010-05-10 KR KR1020117029492A patent/KR20120014583A/ko not_active Withdrawn
- 2010-05-10 ES ES10720884.5T patent/ES2533956T3/es active Active
-
2011
- 2011-11-08 IL IL216224A patent/IL216224A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL216224A0 (en) | 2012-01-31 |
| EP2416761A1 (de) | 2012-02-15 |
| PL2416761T3 (pl) | 2015-07-31 |
| EP2416761B1 (de) | 2015-02-11 |
| CA2761602C (en) | 2015-07-07 |
| US20120128773A1 (en) | 2012-05-24 |
| MX2011011937A (es) | 2012-01-27 |
| KR20120014583A (ko) | 2012-02-17 |
| US9085507B2 (en) | 2015-07-21 |
| CA2761602A1 (en) | 2010-11-18 |
| WO2010130392A1 (de) | 2010-11-18 |
| ES2533956T3 (es) | 2015-04-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO2021013I1 (no) | filgotinib or a salt thereof | |
| CO6970589A2 (es) | Ansolvatos de sal de noribogaina | |
| PL2742051T3 (pl) | Amorficzna postać soli sodowej dolutegrawiru | |
| GB201120097D0 (en) | Cladding element | |
| EP2700049A4 (en) | PREDICTIVE MODELING | |
| EP2685832A4 (en) | STABILIZED HYPOHALOGENOUS ACID SOLUTIONS | |
| PT2623498E (pt) | Sal de sódio de 6-fluoro-3-hidroxi-2-pirazino-carboxamida | |
| PT3421470T (pt) | 5-flúor-1h-pirazolopiridinas substituídas na forma cristalina | |
| BRDI7106579S (pt) | Configuração aplicada em recipiente com padrão ornamental | |
| IL217036A0 (en) | Novel acetylsalicylic acid salts | |
| ZA201306560B (en) | Amorphous (5-fluoro-2-methyl-3-quinolin-2-ylmethyl-indol-1-yl)-acetic acid | |
| GB2489486B (en) | Improvements relating to construction | |
| BRPI1010820A2 (pt) | desfesoterodina na forma de um sal de acido tartarico | |
| EP2785766A4 (en) | HYDROXYPOLYAMINSALZE | |
| PL2677887T3 (pl) | Zmniejszanie wytrącania kwasu sorbinowego | |
| BR112014008574A2 (pt) | composição sólida compreendendo um sal hipotiocianato | |
| CO6890102A2 (es) | Nueva forma de cristal | |
| BR112013011753A2 (pt) | método para produção de sal pirazolinona | |
| TWM389579U (en) | Modeling crystallization ornament | |
| IL212359A0 (en) | Dissolution of salts in situ crystallization ponds | |
| PL394960A1 (pl) | Wewnetrzna trwala ochrona betonu na korozje siarczanowa | |
| GB201105988D0 (en) | Acid formation | |
| BRDI7106004S (pt) | "configuração aplicada a relógio de pulso" | |
| GB201108996D0 (en) | Durable fishing gear float | |
| PL119869U1 (pl) | Prefabrykowana okladzina scienna |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] | ||
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2543 DE 01-10-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |